Patients aged ≤65 years with asthma hospitalized with coronavirus disease 2019 (COVID-19) did not have worse outcomes than hospitalized patients with COVID-19 without asthma, according to the results of a recent study published in the Journal of Allergy and Clinical Immunology.
Medical records from patients who were hospitalized for COVID-19 in the New York City area were evaluated. Outcome measures were compared between patients with asthma and those without to determine if associations existed between the comorbidity and COVID-19 outcomes.
Of the 1298 sequential patients aged <65 years who were hospitalized for COVID-19, the overall prevalence of asthma was 12.6%. It was noted that a subset of younger patients aged <21 years had a higher prevalence at 23.6%. However, when outcomes were evaluated between patients with and without asthma, there were no significant differences in hospital length of stay, need for or duration of intubation, and hospital readmission or mortality between the 2 groups.
“Asthma was not associated with adverse outcomes in severe COVID-19 illness, regardless of age, obesity, or other comorbidities,” the study authors wrote. “[P]opulation-based studies are needed to determine if asthma is a risk factor for developing COVID-19 infection once universal testing becomes readily available.”
Disclosure: One study author declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.
Lovinsky-Desir S, Deshpande DR, De A, et al. Asthma among hospitalized patients with COVID-19 and related outcomes. J Allergy Clin Immunol. Published online August 6, 2020. doi:10.1016/j.jaci.2020.07.026
This article originally appeared on Pulmonology Advisor